linjc16/ctgov huggingface dataset:
Deliberate Ultraviolet Light Exposure to Get a Tan by Young Adult Sexual Minority Males

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to: a) identify enablers and barriers to deliberate ultraviolet light exposure by young sexual minority men (SMM), and b) quantify the extent of their deliberate ultraviolet light exposure.

Detailed Description
-----------------
Aim 1: To develop survey items to assess tanning attitudes and behaviors Nine survey items used by the PI in previous deliberate tanning research were adapted with the expert consensus of members of Northwestern's Institute for Sexual and Gender Minority Health and Wellbeing. Discussions with the PI, research personnel and members of the institute developed the hypothesis that in addition to the previously reported appearance motivations young SMM may be engaging in tanning (indoors or outdoors) as a social activity. A tenth survey item was developed to assess deliberate tanning as a social activity. Aim 2: Analyze the tanning attitudes and behavior data acquired in an online survey of young adult sexual minority males, who regularly participate in the RADAR study. RADAR is a longitudinal study with cohorts from the greater Chicago region recruited between 2008 and 2015. The 10 survey items about tanning attitudes and behaviors were added to the online survey that examines SMMs' behavior in the prior 6 months. This is a secondary analysis of registry data acquired by the RADAR study.

Official Title
-----------------
Analysis of Tanning Attitudes and Behaviors by Young Adult Sexual Minority Males in the Greater Chicago Area

Conditions
-----------------
Sun Sensitivity

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Young adult SMM (age 18-39) Able to read English Have internet access Willing to complete the online survey Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Males who never deliberately tan<br>Males responded to an anonymous online survey that they never deliberately tan | Other: no intervention<br>* This is a secondary analysis of registry data.<br>|
| Males who ever deliberately tan<br>Males responded to an anonymous online survey that they had ever deliberately tan | Other: no intervention<br>* This is a secondary analysis of registry data.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outdoor Tanning Motives | The 95 participants who self-reported deliberate tanning responded to 7 online survey items reported in the analysis population description. | 14 days |
Pain Response During Examination for Retinopathy of Prematurity

Study Overview
=================
Brief Summary
-----------------
Newborns infants equal or less than 1500 grams and/or equal and less than 32 weeks will have ophthalmologic examination for ROP at 6 weeks old. They will be randomized blindly to receive 2 ml of 12.5% dextrose in water (D12.5W) orally five minute before examination (intervention group) or nothing (control). NIPS scale will be applied two minutes before examination and two minutes after examination.

Official Title
-----------------
Evaluation of the Pain Response During Examination for Retinopathy of Prematurity in Very Low Birth Weight Infants

Conditions
-----------------
Retinopathy of Prematurity

Intervention / Treatment
-----------------
* Behavioral: suck 12.5% dextrose in water 5 minutes before the procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all newborns equal or less than 1500 grams birth weight and/or equal or less than 32 weeks gestational age Exclusion Criteria: the ones that died before 6 weeks old

Ages Eligible for Study
-----------------
Minimum Age: 5 Weeks
Maximum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: I<br>this group will receive oral water and glucose prior to eye exam | Behavioral: suck 12.5% dextrose in water 5 minutes before the procedure<br>* Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP<br>|
| No Intervention: II<br>this group is the control group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain secondary to eye examination |  | 2 minutes after the exam | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prematurity, retinopathy of prematurity, pain, very low birth weight infants
Calfactant for Direct Acute Respiratory Distress Syndrome

Study Overview
=================
Brief Summary
-----------------
This study will determine if administration of an suspension of calfactant, a lung surfactant, intratracheally in patients with Direct Acute Respiratory Distress Syndrome within 48 hours of requiring mechanical ventilation can decrease the mortality in patients with lethal disease and shorten the course of respiratory failure in patients with sub-lethal disease.

Detailed Description
-----------------
Recruitment limited to direct adult respiratory distress syndrome patients who have been intubated <48 hours. Origin of ARDS must be infectious pneumonia, aspiration of stomach contents, near drowning, smoke inhalation without pulmonary burn, inhaled industrial gas.

Official Title
-----------------
Calfactant Therapy for Direct Acute Respiratory Distress Syndrome & Direct Acute Lung Injury in Adults and Children

Conditions
-----------------
Respiratory Distress Syndrome, Adult

Intervention / Treatment
-----------------
* Drug: Calfactant
* Drug: Room Air (placebo)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Respiratory failure due to diffuse infectious pneumonia, aspiration, near drowning, smoke inhalation or industrial gas Less than 48 hours of mechanical ventilation Informed consent Exclusion Criteria: Pre-existing lung disease coma limited therapeutic goals (do not resuscitate, etc.) failure of another vital organ

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Calfactant treatment | Drug: Calfactant<br>* Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.<br>* Other names: PneumoSurf;|
| Placebo Comparator: 2<br> | Drug: Room Air (placebo)<br>* Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met<br>* Other names: placebo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality Rate |  | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of mechanical ventilation |  | 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pneumonia, Aspiration, Drowning, inhalation
Follow up of Autoantibodies in Active Tuberculosis

Study Overview
=================
Brief Summary
-----------------
We have previoulsy shown that patients with active Tuberculosis develop a wide array of autoantibodies including rheumatoid factor, anti-CCP, Antinuclear facyor and anti Sm antibodies. The purpose of this study is to evaluate whether the level of autoantibodies decrease after treatment aganist tuberculosis.

Official Title
-----------------
Follow up of Autoantibodies in Active Tuberculosis

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Active Tuberculosis treated Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with tuberculosis | |
| 2<br>Healthy controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Follow up after levels of autoantibodies |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
TB, Patients with tuberculosis
Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Determine the pattern of immunologic reconstitution in patients with T-cell compromise due to DiGeorge syndrome or velocardiofacial syndrome. II. Determine any correlation between immunologic function in these patients and chromosome 22 deletion breakpoints. III. Determine presence of sustained immunologic compromise in older patients.

Detailed Description
-----------------
PROTOCOL OUTLINE: Blood samples are collected at diagnosis of chromosome 22q11 deletion and assessed for lymphocyte proliferation in response to mitogens phytohemagglutinin, pokeweed mitogen, and concanavalin A (mitogen stimulation analyses). These analyses are repeated at 4 months along with a quantitative analysis of immunoglobulin. At 8 months, patients are tested for their lymphocytes' ability to respond to antigens (candida, tetanus, and diphtheria). At 1 year, patients have lymphocyte subset, IgG, IgA, and IgM analyses performed. Quantitative evaluations of antibody titers to diphtheria, tetanus, Haemophilus influenza, and hepatitis B are also performed. Over 1 year of age, all studies are performed if the patient is seen for a single visit.

Official Title
-----------------
Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome

Conditions
-----------------
DiGeorge Syndrome, Shprintzen Syndrome, Chromosome Abnormalities, Abnormalities, Multiple, Conotruncal Cardiac Defects

Participation Criteria
=================
Eligibility Criteria
-----------------
Conotruncal cardiac lesion to be repaired by surgery AND Chromosome 22q11 deletion by FISH

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DiGeorge syndrome, Shprintzen syndrome, cardiovascular and respiratory diseases, conotruncal cardiac defects, genetic diseases and dysmorphic syndromes, rare disease
Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether immunoadsorption is effective in the treatment of severe atopic dermatitis associated with excessively high serum IgE levels.

Official Title
-----------------
Study of Immunoadsorption to Treat Severe Atopical Dermatitis Associated With Excessively High Serum IgE Levels

Conditions
-----------------
Dermatitis, Atopic

Intervention / Treatment
-----------------
* Procedure: immunoadsorption


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Atopical dermatitis Total serum IgE level above 5000 kU/l IGA score of 3 or above No sufficient response to topical corticosteroids/calcineurin inhibitors, UV therapy (at least 4 weeks of therapy), systemic corticosteroids and cyclosporin A (at least 8 weeks of therapy) or no possibility of a prolonged use of this therapy due to adverse events/contraindications 18 years of age or above Effective contraception during therapy Informed consent Exclusion Criteria: Unfavorable conditions for peripheral venous access Known hypersensitivity or allergy towards materials used in the adsorber columns Adequate anticoagulation not possible (e.g. multiple allergies towards various anticoagulants) Extreme bleeding tendency during anticoagulation Hypercoagulability Severe cardiovascular disease forbidding extracorporeal circulation Severe systemic infection Serum IgG level below 250 mg/dl Severe immunodeficiency (e.g. AIDS) Treatment with an ACE inhibitor (discontinue drug at least 72 h before treatment) Pregnancy Lactation A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. chronic alcoholism or mental dysfunction)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Procedure: immunoadsorption<br>* First cycle: week 1, day 1-5 Second cycle: week 5, day 1-5<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of clinical improvement of skin condition, pruritus and sleep disturbance. |  | 13 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of reduction of concomitant topical and/or systemic medication. |  | 13 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Serum Immunoglobulin E above 5000 kU/l
Clinical Performance Evaluation of AQT90 FLEX TnI and TnT

Study Overview
=================
Brief Summary
-----------------
The AQT90 FLEX Troponin I (TnI) and Troponin T (TnT) Tests are in vitro diagnostic assays intended as an aid in the diagnosis of myocardial infarction (MI) in point-of-care and laboratory settings. The purpose of the study is to establish the clinical performance of the AQT90 FLEX TnI and TnT assays for both whole blood and plasma in the intended use population.

Official Title
-----------------
AQT90 FLEX TnI and TnT - Clinical Sensitivity and Specificity Study

Conditions
-----------------
Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is 21 years of age or older. Subject is able to understand information given, and willing and able to voluntarily give their consent to participate in this study. Subject is presenting to the ED with acute chest pain or equivalent ischemic symptoms suggestive of ACS or MI (e.g., acute chest pain/pressure, shortness of breath, discomfort in upper extremity, jaw or epigastrium, diaphoresis, nausea, vomiting, lightheadedness, dizziness, weakness, and/or syncope). Exclusion Criteria: Subject is pregnant or may be pregnant. Subject has an invalid written informed consent or has withdrawn consent.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Acute chest pain or equivalent ischemic symptoms<br>acute chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or acute myocardial infarction (MI) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of acute myocardial infarction (MI) | Diagnosis of acute myocardial infarction (MI) that a subject was experiencing at the time of the subject's presentation to the ED, as determined by independent adjudication panel and based on the Third Universal Definition of Myocardial Infarction. | during the first 24 hours after presentation to the emergency department |
Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis (COCON)

Study Overview
=================
Brief Summary
-----------------
3D FLAIR, 3D T1 FAT SAT, coronal T2 and coronal T1 dixon sequences were usually used to assess visual deficits in MRI. Optic nerve examination is preferably performed using a coronal T2 sequence in order to detect a hypersignal suggestive of inflammation whereas brain examination is preferably performed using a 3D T1 sequence to highlight signs of spatial dissemination and lesions suggestive of multiple slerosis (MS). No study has yet investigated the detection capabilities of 3D T1 for the detection of optic nerve inflammation. The objective of this retrospective study was to determine whether a single 3D T1 sequence allows simultaneous exploration of the optic nerve and the brain for the positive diagnosis of optic neuropathy and/or MS.

Official Title
-----------------
Post-COntrast 3D SE T1 Versus Coronal SE T1-WI MRI in Detecting Optic Neuritis in Patients Presenting With Acute Visual Loss and Otherwise Normal Ophthalmological Examination

Conditions
-----------------
Optic Neuritis, Multiple Sclerosis

Intervention / Treatment
-----------------
* Diagnostic Test: Magnetic Resonance Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Decrease in visual acuity explored in MRI between january 2018 and january 2020 Exclusion Criteria: Past history of episode of Optic neuritis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Magnetic Resonance Imaging|Comparing 3D T1 versus coronal T1 MRI in detecting Optic Neuritis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection of optic neuropathies using MRI | MRI comparison of the diagnostic performance of the 3D T1 sequence and the T1 coronal in the detection of optic neuropathies. | 1 hour |
Effect of Suture for Mesh Fixation in Lichtenstein Hernia Repair

Study Overview
=================
Brief Summary
-----------------
The investigators want to evaluate the effect of suturing the mesh versus using a self-adhesive mesh for Lichtenstein hernia repair. Effect parameters include chronic pain.

Detailed Description
-----------------
Pain is a frequent problem after open inguinal hernia repair. The most frequent operative technique for inguinal hernia repair in adults is the Lichtenstein mesh repair, where a polypropylene mesh is sutured to the tissue in the inguinal region. We therefore want to evaluate the effect of suture for mesh fixation on the occurrence of chronic pain 12 months after operation.

Official Title
-----------------
Effect of Suture for Mesh Fixation in Lichtenstein Hernia Repair, a Prospective Controlled Randomized Trial

Conditions
-----------------
Inguinal Hernia

Intervention / Treatment
-----------------
* Procedure: suture
* Procedure: no suture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy males 18-80 years Primary inguinal unilateral hernia Exclusion Criteria: Recurrent hernia Bilateral, scrotal or femoral hernia BMI above 35

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: no suture<br>self-adhesive mesh, i.e. no suture for mesh fixation | Procedure: no suture<br>* no suture for mesh fixation, because we use a self-adhesive mesh<br>* Other names: Progrip mesh;|
| Experimental: Suture<br>Suture for mesh fixation | Procedure: suture<br>* suture for mesh fixation<br>* Other names: Prolene and Vicryl sutures;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain, Numbness and Discomfort in the Groin | The primary endpoint was a combined measure that evaluated the prevalence of symptoms considered moderate or severe. These symptoms included moderate to severe chronic pain and/or numbness and/or groin discomfort at the 12-month visit. | 12 months after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence | recurrence means recurrence of the hernia defined as a new lump in the inguinal region diagnosed by a surgeon to be a new inguinal hernia. | 12 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain